Wednesday, October 15, 2008 9:53:20 AM
"TORONTO, ONTARIO, Oct 15, 2008 (MARKET WIRE via COMTEX) -- Lorus Therapeutics Inc. (TSX: LOR)(NYSE-A: LRP)("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has received a milestone payment of US$150,000 from Zor Pharmaceuticals LLC ("ZOR"), a subsidiary of Zoticon Bioventures Inc., as it has achieved the milestone of raising the first tranche in financing for the development of Virulizin(R). This will bring the total payment to Lorus to $250,000.
Lorus also announces that Central America has been added to the territories covered in the exclusive licensing agreement with Zor Pharmaceuticals. Due to the extension of the agreement, Lorus will receive an additional US 2 million dollars upon achievement of specific developmental and sales milestones in addition to royalties on sales. The total potential milestone payment from the Virulizin Licensing agreement now exceeds US 12 million dollars.
"The receipt of the initial milestone payment from ZOR is evidence that the market is interested in the continued development of Virulizin(R)," said Dr. Aiping Young, President & CEO of Lorus. "Not only is there a strong potential for Lorus to achieve significant revenues from this license agreement, it is a validation of the company's dedication to the ongoing development of intellectual property - innovations within cancer treatment that Lorus will continue to bring to market from its various active research streams"
Norman
Recent APTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:00:16 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 11:06:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:45:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:26:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:15:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:56:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:52:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:50:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:44:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:39:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:33:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:02:15 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/26/2024 10:30:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 01:00:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/26/2024 05:15:19 AM
- Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] • Edgar (US Regulatory) • 01/26/2024 02:44:21 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/20/2024 02:50:29 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/29/2023 09:10:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 11:30:13 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/11/2023 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 10:28:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 01:15:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM